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Abstract
Aim The aim of this study was to investigate the impact of weight loss following gastric band surgery on multiple measures of
peripheral blood neutrophil (PBN) function.
Material and Methods Twenty-three obese patients undergoing gastric band surgery were recruited to a longitudinal intervention
study, alongside non-obese, healthy gender- and age-matched controls. Eighteen pairs of patients and controls completed all
stages of the study. PBNs were isolated by density centrifugation and a comprehensive analysis of PBN function was undertaken
at various stages of the patients’ bariatric surgical care pathway.
Results Obese patients exhibited exaggerated PBN activity in response to various stimuli, characterised by higher reactive
oxygen species (ROS) generation (n = 18, p < 0.001) and release of pro-inflammatory cytokines (n = 10, p < 0.05) and lower
PBN extracellular trap (NET) formation (n = 18, p < 0.01). PBN chemotactic accuracy was also impaired prior to surgery (n = 18,
p < 0.01). Weight loss was associated with normalised NET production and lower ROS production and cytokine release relative
to healthy controls. However, chemotactic accuracy remained impaired in patients.
Conclusions Weight loss following gastric band surgery was associated with a decrease in the pro-inflammatory activities of
peripheral blood neutrophils (PBNs). A hyper-inflammatory PBN phenotype, involving excess ROS and cytokine release, reduced
NET formation and chemotaxis, may lead to a reduced ability to eliminate infection, alongside inflammation-mediated tissue
damage in obese individuals.
Keywords Chemotaxis . Glycated haemoglobin (HbA1c) . Neutrophil extracellular traps (NETs) . Peripheral blood neutrophil
(PBN) . Reactive oxygen species (ROS) . Very low-calorie diet (VLCD) . Cytokines
Introduction
Worldwide obesity rates have almost doubled since 1980 with
the highest prevalence rates being in developed countries in-
cluding the USA and Europe [1]. 3.4 million adults per year
die from obesity-related complications [2], and obesity is
strongly associated with a range of co-morbid conditions in-
cluding type 2 diabetes, hypercholesterolaemia, hypertension
and obstructive sleep apnoea [3]. Obesity has been shown to
associate with increased mortality rates in influenza [4], the
incidence of urinary tract infections [5] and nosocomial infec-
tions [6], and has positive associations with periodontitis prev-
alence [7]. Possible underlying mechanisms of association
include immune system dysregulation, reduced cell-
mediated immune responses, obesity-related co-morbidities
and altered pharmacological responses [8]. Bariatric surgery
is now considered as a first-line treatment for weight loss in
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individuals with a BMI of ≥ 35 who have co-morbidities and a
BMI of > 40 in the absence of co-morbidity [9].
Peripheral blood neutrophils (PBNs) are sentinels of in-
nate immune responses to infectious agents and the impact
of obesity upon PBN function is therefore worthy of char-
acterisation. PBNs infiltrate inflamed/infected tissues in
increasing numbers in response to a diverse range of im-
munogens and are recruited from the circulation by a series
of chemoattractants, released initially from the inflamed
tissues, which induce gradient-driven chemotaxis. Upon
pathogenic challenge, PBNs are equipped with a variety
of killing mechanisms, including the release of reactive
oxygen species (ROS) [10], pro-inflammatory cytokines
[11] and neutrophil extracellular traps (NETs), which serve
to trap bacteria, facilitating their destruction [12]. Whilst
integral to an effective immune response, dysregulated
PBN behaviour has been reported in many chronic inflam-
matory conditions including rheumatoid arthritis [13], dia-
betes [14] and certain cancers [15].
Therefore, this study aimed to comprehensively analyse
PBN function in morbidly obese individuals prior to and fol-
lowing gastric band surgery (laparoscopic adjustable gastric
band), alongside lean gender- and age-matched healthy
controls.
Materials and Methods
Study Population
Ethical approval for the study was obtained from the North
West Research Ethics Committee (15/NW/07). Patient and
control exclusion criteria included pregnancy and smoking.
Gender- and age-matched healthy controls were recruited
from staff within the School of Dentistry, University of
Birmingham. Exclusion criteria for controls included a BMI
over 27, pregnancy, smoking, evidence of systemic disease
and use of medications/vitamin supplements. Informed con-
sent was obtained from all individual participants included in
the study.
Clinical Pathway for Patients
Patients were initially referred to the medical weight man-
agement services at the Birmingham Heartlands Hospital
by their general medical practitioner. After spending a
defined time period in the weight management clinics
(12–18 months), patients were referred for bariatric sur-
gery. Patients were offered a choice of three bariatric pro-
cedures (laparoscopic adjustable gastric banding, laparo-
scopic sleeve gastrectomy and laparoscopic Roux-en-Y
gastric bypass). To avoid outcome confounding arising
due to the different surgical approaches, only patients
scheduled for gastric banding were offered recruitment
into the current study. All patients were required to en-
gage with a very low-calorie diet (VLCD) for a period of
approximately 8 weeks prior to the procedure (time point
1, T1). The VLCD is part of the treatment regimen as
previous studies have demonstrated reduced post-
operative complication rates in patients [16, 17]. This
was typically 600–800 kcal/day for that defined period.
Patients were usually pre-assessed for surgery 2 weeks
prior to the operation date (time point 2, T2). Patients
were admitted on the day of surgery and following dis-
charge followed up in the dietetic clinics approximately
3 months later (time point 3, T3).
Figure 1 summarises the pathway through the study, which
involved three blood donations at time points within the treat-
ment timeline: prior to a VLCD (T1), pre-surgery (T2) and
post-surgery (T3). BMI (kg/m2) was calculated at each study
visit for each participant.
Collection of Blood and PBN Preparation
Venous blood (24 ml) was collected from the ante-cubital
fossa into Vacutainer™ lithium heparin (17 IU/ml) tubes,
and PBNs were isolated using Percoll density gradients (GE
Healthcare) as previously described [18]. Cell viability, typi-
cally > 98%, was determined by dye exclusion (trypan blue).
Cell purity was determined by cytospin and fluorescence-
activated cell sorting (FACS) on the basis of forward- and
side-scatter characteristics [19].
Blood Chemistry Measurements and Plasma
Preparation
Glycated haemoglobin (HbA1c) was measured using a
HemoCue® HbA1c 501 blood analyser (HemoCue,
Sweden) from whole blood at all three time points. Blood
lipids high-density lipoprotein (HDL), low-density lipoprotein
(LDL), cholesterol and triglycerides (TG) were measured in
whole blood using a CardioChek PA Blood Analyser (BHR
Pharma, UK). Plasma was isolated from blood by centrifuga-
tion (30 min, 1000 rcf, 4 °C; IEC Centra, CL3R), aliquoted
(500 μl) into cryotubes and stored at − 80 °C.
Bacterial Stimulus
Bacterial stimuli employed for the PBN assays included the
oral bacterial species, Streptococcus constellatus
(S. constellatus; ATCC 43146), Fusobacterium nucleatum
(F. nucleatum; ATCC 10953) and Staphylococcus aureus
(S. aureus; ATCC 9144) for toll-like receptors. S. aureus
was opsonised as previously described [20] to facilitate Fcγ-
receptor stimulation.
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Neutrophil Extracellular Trap Release
Neutrophil Extracellular Traps (NETs) were quantified as de-
scribed previously [21]. Briefly, isolated PBNs were stimulat-
ed with S. constellatus (MOI of 300:1), phorbol myristate
acetate (PMA; 50 nM) or hypochlorous acid (HOCl)
(0.75 mM). Following a 3-h incubation, released NET-DNA
was digested with micrococcal nuclease and NETs were de-
tected using Sytox green (Life Technologies; 10 μM).
Fluorescence was measured in arbitrary fluorescence units
(AFU) using a Twinkle LB970 fluorimeter (Berthold
Technologies, USA).
Reactive Oxygen Species Production
Reactive oxygen species (ROS) production was measured
using luminol, isoluminol and lucigenin as substrates for
detecting total HOCl, extracellular HOCl and extracellular
superoxide anion production, respectively, as previously
described [20]. Briefly, PBNs were primed for 30 min with
either GM-CSF (10 ng/ml, equivalent to 100 pg/105 cells)
or PBS and then stimulated with F. nucleatum (MOI 300:1)
or opsonised Staphyloccocus aureus (MOI of 150:1) for
120 min. Peak RLU values were determined pre- and
post-priming/stimulation using a TriStar luminometer
(Berthold Technologies, USA).
PBN Chemotaxis
Chemotaxis was measured by real-time video microscopy
using the Insall bridge chamber as previously described [22].
Briefly, isolated PBNs were introduced into an Insall chamber
and cell movement towards the chemoattractants N-
formylmethionyl-leucyl-phenylalanine (fMLP, 10 nM) and in-
terleukin 8 (CXCL8, 200 ng/ml) analysed using a Zeiss
Primovert microscope (Carl Zeiss Imaging, Thornwood, NY,
USA). The resultant numerical data generated were used to
measure chemotactic accuracy, defined in terms of speed, ve-
locity (directed movement) and chemotactic index (orienta-
tional accuracy).
PBN Cytokine Release
Isolated PBNs were cultured for 18 h as previously described
[23]. PBNs were stimulated with F. nucleatum (MOI 300:1),
opsonised S. aureus (MOI 300:1) or with LPS (5 μg/ml per
well) derived from Escherichia coli (Sigma, UK). Cells were
pelleted by centrifugation (10 min, 2000 rcf) and superna-
tants were harvested and stored at – 80 °C for subsequent
Fig. 1 Participant flow diagram.
Patients were recruited within the
bariatric surgical pathway; all
appointments that coincided with
study involvement are
highlighted in black. Obese
participants were initially
recruited verbally during the
dietician’s session that laid out
treatment options. Participants
were required to follow a very
low-calorie diet (VLCD) of their
choice (Cambridge Weight
Plan®, Weightwatchers® or re-
striction to 1000 cal per day by
consuming a varied diet or a diet
limited to foods, such as milk and
yoghurt). Blood samples were
taken at three different time points
coinciding with patient atten-
dance at bariatric clinical ap-
pointments. Time/weight changes
shown as mean, ±standard devia-
tion and range
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cytokine quantification. Pro-inflammatory cytokines
interleukin-1β (IL-1β), interleukin-8 (CXCL8), interleukin-
6 (IL-6) and tumour necrosis factor-α (TNFα) were quanti-
fied using Procartaplex™ multiplex immunoassays
(Affymetrix eBioscence) from the first ten undiluted patient
and control cell culture supernatants and also from patient
plasma samples according to the manufacturer’s instructions.
Mean fluorescence intensity (MFI) was measured on a
Luminex 100/200 platform (USA) in the Clinical
Immunology labs at the University of Birmingham. Plasma
levels of the PBN serine protease myeloperoxidase (MPO)
and the epithelial cell-derived neutrophil-activating peptide
ENA-78 were measured by ELISA using commercially
available kits (R&D systems, UK).
Statistical Analysis
Weight loss was expressed as change in weight and excess %
BMI loss between designated time points. All data was
analysed statistically using GraphPad Prism 5 (version 5.0;
GraphPad Software, CA, USA). Normality of data was deter-
mined using the Kolmogorov–Smirnov test, and all statistical
comparisons were performed using non-parametric methods,
as indicated in the text and figures. Previous studies of neu-
trophil functional assay report day-to-day variation [20,
24–26]. It was necessary to present the data as a ratio by
dividing patient values by controls per result per time point.
Results
Patient Demographic
Twenty-three patients were enrolled onto the study and five
chose to withdraw due to changes in surgical choice and for
personal reasons. Eighteen patients (17 females, 1 male; mean
age ± SD = 48 ± 11 years) underwent gastric band surgery.
Initial mean referral weight and BMI of the patients were
129.5 kg ± 19.5 and 49 ± 7.3, respectively. At 3 months’
post-surgery, average weight was 119.7 ± 15.8 and excess %
BMI loss was 14.6% ± 7. Demographic information is shown
in Table 1 and Fig. 1 summarises patient withdrawal points.
Plasma Biochemistry
Comparisons between patients and controls demonstrated
differences at T1 for HbA1c, HDL and LDL/HDL ratio
(Table 2). Significance was evident between patient and
controls for HbA1c (p < 0.001), HDL (p < 0.01) LDL/
HDL (p < 0.05) and TG (p < 0.01) at time point 1.
Significance was lost for all outcomes except HDL levels
(p < 0.01) by T3, which remained significantly lower in
patients versus controls.
NET Quantification
At T1 NET formation (Fig. 2(a)) was significantly lower in
patient PBNs relative to controls for all stimuli employed
(p < 0.05 and p < 0.01 for HOCl). Statistical significance
remained at T2 (Fig. 2(b)) for HOCl (p < 0.05) and was lost
completely by T3 (Fig. 2(c)). NET production was also com-
pared between time points. There were significant differences
in NET production by patient PBNs between T1 and T3 for
PMA and HOCl, indicating that weight loss is associated with
an increase in NET production. Overall NET production in-
creased following weight loss in gastric band patients.
ROS Generation
PBNs from gastric band surgery patients released signifi-
cantly higher levels of ROS in the presence of a stimulus
and following priming and stimulation at T1 with all three
chemiluminescent reagents (Fig. 3). Over the course of the
different study time points, significant differences remained
for luminol (Fig. 3(a–c)) and were partially lost for
isoluminol (Fig. 3(d–f)) and lucigenin (Fig. 3(g–i)).
Overall, weight loss in the patients was accompanied by a
reduction in the levels of ROS release when compared with
healthy controls. There were no significant differences in
ROS production by patient PBNs across the three time
points (Supplementary Fig. 1).
Chemotaxis
Significant differences were detected between patient and
control PBNs at all the three time points for speed, velocity
and CI, with patient PBNmovement being lower compared to
controls (Fig. 4). Weight loss in patients was not accompanied
by improvements in PBN chemotactic accuracy relative to
controls. Chemotaxis was also compared across the different
time points in patients (Fig. 4(d, h, l)). There were significant
differences between T1 and T3 with speed and velocity in
response to both fMLP and CXCL8, with a trend towards an
overall increase in speed from T1 to T3. There were no sig-
nificant differences for control values across any of the time
points. Weight loss following gastric band surgery was asso-
ciated with an increase in chemotactic accuracy, but this did
not reach control patient levels.
Pro-inflammatory Cytokine Release
Pro-inflammatory cytokines IL-1β, IL-6, CXCL8 and TNFα
were measured in both plasmas (Table 2) in addition to cell
culture supernatants (Supplementary Fig. 2) representing po-
tential localised and systemic effects for all the three time
points respectively. Patient PBNs released significantly higher
levels of cytokines, both in the absence and presence of
OBES SURG
stimuli at T1 compared with controls (p < 0.05) with some
significant differences remaining at T2. There were no differ-
ences remaining between patients and controls by T3. The
data indicate that weight loss is accompanied by a reduction
in pro-inflammatory cytokine release.
Whilst there were no differences in the plasma concentrations
of cytokines between patients and controls, the neutrophil-
derived enzyme MPO and the neutrophil-activating peptide
ENA-78 (Table 2) were significantly reduced (MPO, p
< 0.0001, Wilcoxon matched-pairs; ENA-78, p < 0.001,
Table 2 Blood biochemistry of patients and controls at each time point.
Plasma was collected and the detected cytokines CXCL8 and TNFαwere
measured in patients (n = 10) and controls (n = 10) per time point
respectively (n = 10). IL-1β and IL-6 were tested but not detected at high
enough levels (data not shown). In addition, the neutrophil-activating
peptide ENA-78 and enzyme MPO were also measured (n = 18). n.d.
not detected. Data shown as mean, ±standard deviation and range.
Statistical test: Wilcoxon matched-pairs. *p < 0.05, **p < 0.01, ***p
< 0.001
Analyte T1 T2 T3
Control Patient Control Patient Control Patient
HbA1c 5.4 ± 1*** 7.1 ± 1.4 5.1 ± 0.45*** 6.7 ± 1.1 5.6 ± 0.77 5.5 ± 0.9
(4.2–6.4) (5.1–9.7) (4.5–5.8) (5.1–8.6) (4.5–6.8) (4.5–8.3)
Cholesterol 195 ± 43 166 ± 50 183 ± 43* 148 ± −47 183 ± 36 162 ± 43
(136–264) (114–336) (110–257) (100–305) (132–279) (113–256)
HDL 75 ± 15 54 ± 13** 68 ± 18 48 ± 14** 72 ± 16 58 ± 17*
(48–100) (37–84) (35–100) (33–84) (41–100) (36–84)
LDL 83 ± 37 84 ± 43 77 ± 37 80 ± 45 88 ± 36 82 ± 38
(45–152) (42–219) (40–155) (32–226) (39–189) (17–154)
LDL/HDL 1.2 ± 0.6 1.6 ± 0.8* 1.3 ± 0.8 1.8 ± 1.2* 1.3 ± 0.7 1.5 ± 0.7
(0.5–2.3) (0.5–3.8) (0.5–3.3) (0.4–5.3) (0.5–2.8) (0.2–2.7)
TG 95 ± 38 143 ± 62* 89 ± 49 121 ± −55* 91 ± 31 117 ± 56
(50–187) (63–292) (50–244) (51–262) (50–170) (50–250)
TNFα 12.5 ± 1.18 12.8 ± 3.49 n.d. n.d. n.d. n.d.
(10–14.3) (11.5–15.7)
CXCL8 3.27 ± 1.18 3.49 ± 2.35 1.78 ± 1.67 1.69 ± 1.67 1.39 ± 0.88 1.34 ± 0.78
(2.4–5.3) (1.59–9.2) (0–5.2) (0–5) (0–2.54) (0–2.39)
ENA-78 599.5 ± 516 1045.5 ± 1452.6 Not analysed Not analysed 321.9 ± 262.2 66.6 ± 34.8***
(121.1–1855.3) (103.8–5234.1) (66.2–998.1) (34.7–169.6)
MPO 162.4 ± 66.3 199.7 ± 160.8 Not analysed Not analysed 101.8 ± 60.9 18.6 ± 12.68***
(30.3–241.7) (28.1–652.5) (29.6–303.8) (8–49.6)
Table 1 Characteristics of gastric band patients and controls
Control Patient
Female:male ratio 17:01 17:01
Mean age ± SD (range) 47 ± 9.8 (27–65) 48 ± 10.5 (24–67)
No. with a single morbidity n/a 4
No. with > 2 co-morbidities n/a 12
No. with diabetes (type 2) n/a 7
No. taking lipid-lowering drugs n/a 7
BMI at first blood collection (time point 1) mean ± SD (range) 23 ± 2.2 (19–27) 49 ± 7.3 (38–62)
BMI at second blood collection (time point 2) mean ± SD (range) 23 ± 2.2 (19–25.5) 47 ± 7.3 (36–59)
BMI at final blood collection (time point 3) mean ± SD (range) 23 ± 1.8 (20–26) 43 ± 6 (33–54)
Mean overall % weight loss (T1–3) ± SD (range) n/a 14.6 ± 7.1 (0.17–30.2)
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Wilcoxon matched-pairs) following weight loss, suggesting an
overall reduction in the systemic inflammatory burden.
Discussion
The aim of this study was to comprehensively characterise for
the first time potential changes in PBN behaviour following
weight loss in morbidly obese individuals at three different
time points: during the course of a VLCD, and pre- and
post-gastric band surgery. As expected, overall BMI reduced
following a VLCD and 3 months’ post-surgery (BMI loss was
4.5% at T2 and 14.6% at T3). However, despite the weight
loss, many patients (n = 13) still had a BMI of > 40 at the end
of the 3-month follow-up, which may lead to residual alter-
ations in patients’ immune status and specifically, a residual
low-grade chronic inflammatory state.
Lipid profiles of obese patients showed an improvement
following weight loss when compared with controls within
each time point. Improved lipid profiles have been reported
in other studies of weight loss in obese patients [27–29], and
whilst our results support this finding, the patient values are
more subdued which could be a result of shorter follow-up
monitoring relative to other studies which measure blood lipid
levels for an extended period of time (up to 4 years). In addi-
tion, the small sample size in the present study, the limited
information on diet practices following surgery and differ-
ences in blood collection times (morning versus afternoon)
which can contribute to varied results [30] may underlie the
subdued results presented here.
Patient NET release was significantly lower than non-obese
controls prior to weight loss and NET production increased in
patients relative to controls during the course of their weight
loss. These results are in conflict with previous studies in
Fig. 2 Patient and control NET release at different time points. PBNs
were isolated and NETs were quantified in response to direct receptor-
independent stimulation using PMA (50 nM) and HOCl (0.75 mM), and
via the toll-like receptor (TLR) pathway S. constellatus (MOI 1 in 500).
Data presented as box and whisker plots (a–c) for patient (red bars) and
controls (blue bars) respectively. *p < 0.05, **p < 0.01. Statistical test for
a–c was Wilcoxon matched-pairs. Data presented as patient/control ratios
(d). n = 18 for total patient and controls respectively. Statistical test:
Friedman and Dunn’s post-test
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Fig. 3 Patient and control ROS
production at different time
points. PBN ROS generation was
detected following priming with/
without GM-CSF (10 ng/ml) and
stimulation using opsonised
S. aureus (MOI 1 in 150) for Fcγ
receptor stimulation and
F. nucleatum (MOI 1 in 300) for
TLR stimulation. Data presented
as box and whisker plots. n = 18
for total patient (red bars) and
controls (blue bars) respectively
for time points 1 (a), 2 (b) and 3
(c). Statistical test was Wilcoxon
matched-pairs. Data was also
normalised (patient/control) and
compared between the time points
(d). Statistical test was Friedman
and Dunn’s post-test, *p < 0.05,
**p < 0.01
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which NET release was reported to be exaggerated during
states of chronic inflammation, such as chronic obstructive
airways disease [31] and certain vasculitides [32]. The under-
lying reasons for the results presented here could be due to the
administration of anti-inflammatory medications which are
commonly used as a treatment for obese patients [33] and
have been demonstrated to lower NET formation [34].
Increased PBN ROS production has been reported to be
associated with adiposity, leading to an elevation of systemic
oxidative stress due to lipid peroxidation and direct oxidative
injury [35, 36] affecting other organs including the liver and
aorta [37]. Moreover, elevated lipid and glucose levels are
reported to stimulate superoxide production via PKC-
dependent activation of vascular NADPH oxidase in cultured
endothelial cells [38]. Enhanced ROS release was detected in
patient PBNs compared to control PBNs prior to weight loss
in all the three chemiluminescent assays employed.
Significant differences between patients and controls
remained at both subsequent time points for total ROS release
(luminol), indicating that despite the weight loss, PBNs from
obese patients were still in a hyper-reactive state. Extracellular
HOCl release (isoluminol) and superoxide (lucigenin) release
reduced by T3 compared to controls, indicating a partial re-
duction in PBN hyper-reactivity following weight loss. This is
consistent with previous studies investigating PBN ROS pro-
duction in obese compared to lean individuals [39].
Few studies have investigated the effects of obesity on
PBN chemotaxis during the course of weight loss. However,
studies of chemotactic activity from type 2 diabetes patients
report defective PBN functions including defective chemotax-
is [40]. Advanced glycation end products (AGEs) have been
shown to interfere with leukocyte function, inducing changes
in intracellular calcium and actin polymerisation and subse-
quent impaired chemotaxis [41]. This suggests that exposure
to AGEs, levels of which are known to be raised in obese
individuals [42], may be a potential reason for the reduced
PBN chemotactic accuracy detected in our study.
Pro-inflammatory cytokine release from PBN culture su-
pernatants revealed significantly higher levels compared to
controls with the stimuli used. Significance was evident with
IL-1β, IL-6, CXCL8 and TNFα at T1 in the presence of
various stimuli for TNFα only in the absence of a stimulus.
These results are consistent with a hyperactive and hyper-
reactive PBN phenotype, which was moderated to a degree
by T3, when pro-inflammatory cytokine release in patients
relative to control levels.
Longitudinal patient analysis revealed a reduction in IL-1β,
IL-6 and TNFα over time for some stimuli, demonstrating that
Fig. 4 PBN chemotaxis in patients and controls at different time points.
PBN chemotaxis was performed and cells analysed. Tracked information
was used to generate average speed (a–c), velocity (e–g) and CI (i–k) for
patient and control PBNs at each time point (1/2/3) in the presence of
RPMI (negative control), fMLP (10 nM) and CXCL8 (200 ng/ml)
chemoattractants. Data shown as box and whisker plots (n = 18; 15 cells
tracked per chemoattractant/RPMI) for patient (red bars) and control (blue
bars). Statistical test was Wilcoxon matched-pairs, *p < 0.05,
***p < 0.001, ****p < 0.0001. For time point comparison (d, h, l), the
data is presented as raw values because of low numerical variability
enabling statistical analyses without the need for data normalisation (as
was done for the ROS and NET analysis). n = 18 for total patient and
controls respectively. Statistical test was Friedman and Dunn’s post-test,
*p < 0.05, **p < 0.01, ***p < 0.001
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weight loss was associated with a decrease in systemic pro-
inflammatory cytokine levels. These results are in agreement
with reports within the literature regarding increased serum
cytokine levels in obesity [43–45] reflecting a level of immune
system activation. Systemic TNFα levels have been shown to
correlate with increasing BMI [46]. TNFα has been shown to
act directly upon adipocytes and altered levels have been sug-
gested to interfere with glycaemic homeostasis and promote
greater insulin resistance [47] as well as promoting endothelial
dysfunction by inducing NF-κB signalling, NADPH activation
and ROS production [48, 49]. Circulating pro-inflammatory
cytokines have also been shown to prime PBNs [50] which
may account for their enhanced production in our study when
PBNs were stimulated. Other disorders of inflammation have
also been reported to associate with enhanced PBN ROS re-
lease [51] in addition to enhanced pro-inflammatory cytokine
production [52].
Several cell types have been shown to be exaggeratedly
affected from the inflammatory insult during obese condition
caused by nutrient overload, specifically increase circulating
levels of fatty acids, on the metabolic cells. Effects on immune
cell signalling include up-regulation of the genes encoding for
cytokines, chemokines and other inflammatory mediators
through activated transcription factors—nuclear factor-kB, ac-
tivator protein-1, nuclear factor of activated T cells and signal
transducer and activator of transcription 3 [53–55]. One recent
study in mice fed a high-fat diet demonstrated reduced expres-
sion of peroxisome proliferator receptor gamma (PPARg), an
anti-inflammatory nuclear factor, in bone marrow neutrophils;
suppression of PPARg; increased neutrophil cytokine expres-
sion in blood neutrophils, and their infiltration into adipose
tissues of high-fat diet-fed mice, in addition to increases
p65/NFkB transcriptional activity [56]. To our knowledge,
no studies have been conducted on PBN downstream signal-
ling in obese individuals prior to and following gastric band
surgery, and this represents an attractive avenue for further
study.
MPO and ENA-78 were measured in plasma as markers
of systemic or tissue neutrophil activation. ENA-78 is an
epithelial cell-derived neutrophil-activating peptide that is
increased in s i tes of in f lammat ion . I t ac t s as a
chemoattractant for PBNs, has angiogenic properties and
is reported to contribute to cancer progression [57]. The data
presented here show a marked reduction in MPO and ENA-
78 levels with weight loss, suggesting the overall positive
effects of weight loss on the chronic inflammatory state that
defines obesity.
Limitations of the reported studies include the relatively
small sample size (n = 18 pairs of participants) and presence
of co-morbidities within the obese patients; 11 patients suf-
fered from obstructive sleep apnoea (OSA), a disorder
characterised by repetitive pauses of breathing caused by par-
tial or complete collapses of upper airways during sleep [58].
The associated potential for hypoxia may stimulate peripheral
blood cells, including PBNs, and can lead to increased pro-
duction of ROS [59], endothelial dysfunction [60] and pro-
inflammatory cytokine production [61]. Due to limited patient
background information, it was not possible to determine the
OSA status of patients during the study or if the extent of
weight loss had impacted on their condition. Another limita-
tion is the relatively short post-operative follow-up time of
3 months owing to reduced number of clinical appointments
patients have with the surgical team rendering blood collec-
tion impractical; future studies would be aimed at including
additional donations for a more in-depth comparison of PBN
functional change.
In summary, the reported studies have characterised PBN
behaviour in obesity prior to and following interventional
weight loss for the first time using novel assays of neutrophil
function. The data reported supports the idea that circulating
PBNs are involved in obesity-related inflammation and that
normalisation of the PBN behaviour relative to healthy con-
trols is reflected by improvements in overall health of the
patients as measured in terms of reduced circulating pro-
inflammatory cytokines and more favourable blood chemistry
measurements. PBNs from obese patients exhibit higher ROS
generation and release of cytokines, which appears to enhance
the extent of local and systemic inflammation. Weight loss
was associated with improved outcomes broadly characterised
by lower ROS production and cytokine release relative to
healthy controls. Chemotactic accuracy following weight loss
did not improve suggesting either longer-term therapy or en-
vironmental factors are required to restore PBN-directed
movement.
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